Hongqiao International Institue of Medicine & Clinical Research Center, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Cell Mol Med. 2022 Aug;26(15):4322-4332. doi: 10.1111/jcmm.17454. Epub 2022 Jun 28.
The high mobility group box 1 (HMGB1) is a potential biomarker and therapeutic target in various human diseases. However, a systematic, comprehensive pan-cancer analysis of HMGB1 in human cancers remains to be reported. This study analysed the genetic alteration, RNA expression profiling and DNA methylation of HMGB1 in more than 30 types of tumours. It is worth noting that HMGB1 is overexpressed in malignant tissues, including lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD) and thymoma (THYM). Interestingly, there is a positive correlation between the high expression of HMGB1 and the high survival prognosis of THYM. Finally, this study comprehensively evaluates the genetic variation of HMGB1 in human malignant tumours. As a prospective biomarker of COVID-19, the role that HMGB1 plays in THYM is highlighted.
高迁移率族蛋白 B1（HMGB1）是多种人类疾病的潜在生物标志物和治疗靶点。然而，HMGB1 在人类癌症中的系统、全面的泛癌分析仍有待报道。本研究分析了超过 30 种肿瘤中 HMGB1 的遗传改变、RNA 表达谱和 DNA 甲基化。值得注意的是，HMGB1 在恶性组织中过度表达，包括淋巴样肿瘤弥漫性大 B 细胞淋巴瘤（DLBC）、胰腺腺癌（PAAD）和胸腺瘤（THYM）。有趣的是，HMGB1 的高表达与 THYM 的高生存预后呈正相关。最后，本研究全面评估了 HMGB1 在人类恶性肿瘤中的遗传变异。作为 COVID-19 的一个有前景的生物标志物，HMGB1 在 THYM 中的作用被强调。
